Journal list menu
IssueAlimentary Pharmacology & Therapeutics: Volume 58, Issue 5
i, 489-557September 2023
Export Citations
Download PDFs
FEATURED COVER
Featured Cover
- Page: i
- First Published: 10 August 2023
The cover image is based on the Original Article Donor, patient age and exposure to antibiotics are associated with the outcome of faecal microbiota transplantation for recurrent Clostridioides difficile infection: A prospective cohort study by Simon M. D. Baunwall et al., https://doi.org/10.1111/apt.17642 Image Credit: Nina Rågård
ISSUE INFORMATION
REVIEW ARTICLE
Review article: Translating STRIDE-II into clinical reality – Opportunities and challenges
- Pages: 492-502
- First Published: 29 June 2023
Treat-to-target approach for IBD patients.
F.M.T. FOR RECURRENT C. DIFFICILE INFECTION
Donor, patient age and exposure to antibiotics are associated with the outcome of faecal microbiota transplantation for recurrent Clostridioides difficile infection: A prospective cohort study
- Pages: 503-515
- First Published: 22 July 2023
Donor, patient age and exposure to antibiotics are associated with the outcome of faecal microbiota transplantation for recurrent Clostridioides difficile infection: A prospective cohort study.
DIETARY FIBRE AND RISK OF I.B.D.
Higher dietary fibre intake is associated with lower risk of inflammatory bowel disease: prospective cohort study
- Pages: 516-525
- First Published: 18 July 2023
EPIDEMIOLOGY OF NAFLD IN SOUTH AMERICA
Epidemiology and risk factors for histopathologic characteristics of non-alcoholic fatty liver disease in South America
- Pages: 526-536
- First Published: 22 June 2023
Large retrospective study addressing NAFLD in 5 countries in South America including >2500 patients. Associations with comorbidities and liver fibrosis were performed. Diabetes, hypertension and the metabolic syndrome were associated with higher liver fibrosis.
SOCIAL DETERMINANTS OF HEALTH AND STEATOTIC LIVER DISEASE
Effects of social determinants of health on mortality and incident liver-related events and cardiovascular disease in steatotic liver disease
- Pages: 537-545
- First Published: 03 July 2023
INVITED EDITORIALS
Editorial: Is vedolizumab the preferred biologic therapy for biologic-naïve patients with ulcerative colitis?
- Pages: 546-547
- First Published: 10 August 2023
This article is linked to Bokemeyer et al paper. To view this article, visit https://doi.org/10.1111/apt.17616
Editorial: Mitigating the risk of severe hepatitis flare following nucleoside analogue discontinuation—Insights from a real-world study
- Pages: 548-549
- First Published: 10 August 2023
This article is linked to Hsu et al papers. To view these articles, visit https://doi.org/10.1111/apt.17614 and https://doi.org/10.1111/apt.17644
Editorial: Mitigating the risk of severe hepatitis flare following nucleoside analogue discontinuation—Insights from a real-world study. Authors' reply
- Pages: 550-551
- First Published: 10 August 2023
This article is linked to Hsu et al papers. To view these articles, visit https://doi.org/10.1111/apt.17614 and https://doi.org/10.1111/apt.17630
Editorial: Social determinants of health in steatotic liver disease—Generating community-level data to maximise community impact
- Pages: 552-553
- First Published: 10 August 2023
This article is linked to Chen et al paper. To view this article, visit https://doi.org/10.1111/apt.17631
Editorial: One step closer to personalised nutrition therapy for irritable bowel syndrome
- Pages: 554-555
- First Published: 10 August 2023
This article is linked to Wilson et al paper. To view this article, visit https://doi.org/10.1111/apt.17609
LETTER TO THE EDITOR
Letter: Elderly onset inflammatory bowel disease—Treat to target approach is still warranted
- Pages: 556-557
- First Published: 10 August 2023
This article is linked to Nørgård et al paper. To view this article, visit https://doi.org/10.1111/apt.17520